drugset
Drugs / Equine immunoglobulin anti SARS-CoV-2
last change Dec 2020 re-read 3 minutes ago

Equine immunoglobulin anti SARS-CoV-2

Protein / enzyme biologic

Developed for
COVID-19
Investigated by
Costa Rican Social Security Fund · Ministry of Health Costa Rica · Universidad de Costa Rica

Trials 1

today NCT04610502 · Ph 2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04610502 Sep → Oct 2020 COVID-19 Costa Rican Social Security Fund Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Equine immunoglobulin anti SARS-CoV-2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04610502 ↗
Modality Protein / enzyme biologic “Equine immunoglobulin anti SARS-CoV-2” NCT04610502 ↗
Route Intravenous “a vial of 10ml of the drug during 1 hour Intravenously” NCT04610502 ↗